Data Foundry

Drug recalls 2025

Xolair — Class II drug recall D-0571-2025

Ongoing recall by Cardinal Health Inc., reported 2025-08-13, distributed nationwide. CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Recall numberD-0571-2025
Product typeDrug
ClassificationClass II
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmCardinal Health Inc., Dublin, OH, United States
Recall initiated2025-07-30
Classified2025-08-07
Reported by FDA2025-08-13
DistributedNationwide (US)
Quantity6 units
Reason classeslabeling, cgmp
NDC50242-0040, 50242-0040-62, 50242-0040-86, 50242-0214, 50242-0214-01, 50242-0214-03, 50242-0214-55, 50242-0214-83, 50242-0214-86, 50242-0214-99, 50242-0215, 50242-0215-01, 50242-0215-03, 50242-0215-55, 50242-0215-83, 50242-0215-86, 50242-0215-99, 50242-0227, 50242-0227-01, 50242-0227-55, 50242-0227-86, 50242-0227-99
Lot numbers3617756
Expiration dates2025-12-31

Product

Xolair (omalizumab injection), 150 mg/ml, 1 auto-injector, Rx only, Genentech, Inc, South San Francisco, CA 9408, NDC: 50242-215-55.

Reason for recall

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0571-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.